C$0.09
0.00%
Toronto, Sep 28, 04:00 pm EDT. Closed.
ISIN
CA81732W1041
Symbol
SVA

Sernova Stock price

C$0.09
-0.02 18.18% 1M
-0.07 41.94% 6M
-0.04 30.77% YTD
-0.10 51.35% 1Y
-0.67 88.16% 3Y
-1.17 92.86% 5Y
-0.21 70.00% 10Y
-0.25 73.13% 20Y
Toronto, Closing price Mon, Sep 28 2026
+0.00 0.00%
ISIN
CA81732W1041
Symbol
SVA
Industry

Is Sernova a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
C$34.0m
Enterprise Value
C$35.4m
Net debt
C$2.5m
Cash
C$60.0k
Shares outstanding
377.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-3,281.4%
Return on Equity
62.8%
ROCE
76.4%
ROIC
106.4%
Debt/Equity
-0.2
Financials (TTM | estimate)
Revenue
C$0.0 | C$0.0
EBITDA
C$-8.9m
EBIT
C$-8.9m
Net Income
C$-10.3m
Free Cash Flow
C$-4.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
47.5%
EBIT
48.4%
Net Income
44.4%
Free Cash Flow
69.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
C$0.0
FCF per Share
C$0.0
Short interest
-
Employees
8
Rev per Employee
C$0.0

Sernova Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Sernova forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Sernova forecast:

Buy
80%
Hold
20%

Financial data from Sernova

Jul '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.80 6.80
14% 14%
-
- Research and Development Expense 2.05 2.05
77% 77%
-
-8.85 -8.85
48% 48%
-
- Depreciation and Amortization 0.08 0.08
82% 82%
-
EBIT (Operating Income) EBIT -8.93 -8.93
48% 48%
-
Net Profit -10 -10
44% 44%
-

In millions CAD.

Don't miss a Thing! We will send you all news about Sernova directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sernova Stock News

Neutral
GlobeNewsWire
●
4 days ago
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform
Neutral
GlobeNewsWire
●
3 months ago
TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for...

Company Profile

Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. The firm also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes. The company was founded on August 19, 1998 and is headquartered in London, Canada.

Head office Canada
CEO Mr. Rigby
Employees 8
Founded 1998
Website sernova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today